LIGAND-AI Protein-ligand data generation at scale to support computational hit finding and optimization
- Coordinator
- Structural Genomics Consortium Lbg, United Kingdom
- Runs
- 1 November 2025 to 31 October 2030
- Status
- Running
- EU funding
- €29.9m
- Total cost
- €61.2m
- Partners
- 22 organisations in 11 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101252959
What the project is doing
In the project's own words, from its summary on CORDIS.
The ability to discover and optimize small-molecule ligands by using innovative physics-based, machine learning (ML) and artificial intelligence (AI) approaches would transform and democratize the discovery of new small molecule drugs and related research tools (chemical probes), with important implications for the development of new medicines for rare and pediatric diseases, cancer, and women’s health. The development of these methods is being held back by the lack of high-quality protein-ligand data in the public domain.
To fill this gap, we have assembled a multi-sector public-private partnership that will generate high-quality, ML-ready, open protein-ligand data at scale and as a public good, and will engage with the research community to build, benchmark and test new machine learning models for small molecule discovery and optimization. Our ambition is to identify drug starting points for >500 human proteins and transform and democratize small molecule drug discovery.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Structural Genomics Consortium Lbg | London | United Kingdom | Coordinator |
| Universidade Estadual De Campinas | Campinas Sp | Brazil | Associatedpartner |
| The Hospital for Sick Children | Toronto | Canada | Participant |
| University Health Network | Toronto | Canada | Participant |
| HitGen Inc | Chengdu | China | Associatedpartner |
| Enamine Germany GmbH | Frankfurt am Main | Germany | Participant |
| European Molecular Biology Laboratory | Heidelberg | Germany | Participant |
| Johann Wolfgang Goethe-Universitaet Frankfurt Am Main | Frankfurt Am Main | Germany | Participant |
| Nuvisan Icb GmbH | Berlin | Germany | Participant |
| Pfizer Pharma GmbH | Berlin | Germany | Associatedpartner |
| Thermo Fisher Scientific (bremen) GmbH | Bremen | Germany | Participant |
| Novo Nordisk A/s | Bagsvaerd | Denmark | Participant |
| Fundacio Privada Institut D'investigacio Oncologica De Vall-Hebron (vhio) | Barcelona | Spain | Participant |
| Ibm Israel - Science and Technology Ltd | Petach Tikva | Israel | Participant |
| Astrazeneca AB | Sodertaelje | Sweden | Associatedpartner |
| Chemspace Limited Liability Company | Kyiv | Ukraine | Participant |
| Abcam Limited | Cambridge | United Kingdom | Participant |
| Astrazeneca UK Limited | Cambridge | United Kingdom | Participant |
| Pfizer R&D UK Limited | Sandwich | United Kingdom | Associatedpartner |
| University College London | London | United Kingdom | Participant |
| Vernalis (r&d) Limited | Cambridge | United Kingdom | Participant |
| Pfizer Inc | New York City | United States | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI